249 related articles for article (PubMed ID: 35316675)
21. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
[TBL] [Abstract][Full Text] [Related]
22. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
[TBL] [Abstract][Full Text] [Related]
23. Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study.
Marrone A; Nevola R; Sellitto A; Cozzolino D; Romano C; Cuomo G; Aprea C; Schwartzbaum MXP; Ricozzi C; Imbriani S; Rinaldi L; Gjeloshi K; Padula A; Ranieri R; Ruosi C; Meo LA; Abitabile M; Cinone F; Carusone C; Adinolfi LE
Clin Infect Dis; 2022 Aug; 75(1):e403-e409. PubMed ID: 35084022
[TBL] [Abstract][Full Text] [Related]
24. Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.
Tanimoto T; Tada S; Fujita S; Hirakawa T; Matsumura M; Isoyama S; Ueno S; Hamai K; Tsuji N; Hirosawa H; Taniguchi T; Okamoto T; Omoto T; Kusunoki S; Maeda H; Ishikawa N
Respir Investig; 2022 May; 60(3):418-424. PubMed ID: 35307364
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
[TBL] [Abstract][Full Text] [Related]
26. Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia.
Cacho J; Burgos E; Molina M; Villegas A; Pérez M; Cañas L; Taco O; Juega J; Lauzurica R
Nefrologia (Engl Ed); 2022; 42(3):311-317. PubMed ID: 36210620
[TBL] [Abstract][Full Text] [Related]
27. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
Goletti D; Cantini F
N Engl J Med; 2021 Mar; 384(9):867-869. PubMed ID: 33657299
[No Abstract] [Full Text] [Related]
28. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Titanji BK; Farley MM; Mehta A; Connor-Schuler R; Moanna A; Cribbs SK; O'Shea J; DeSilva K; Chan B; Edwards A; Gavegnano C; Schinazi RF; Marconi VC
Clin Infect Dis; 2021 Apr; 72(7):1247-1250. PubMed ID: 32597466
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan.
Hirasawa Y; Terada J; Shionoya Y; Fujikawa A; Isaka Y; Takeshita Y; Kinouchi T; Koshikawa K; Tajima H; Kinoshita T; Tada Y; Tatsumi K; Tsushima K
Respir Investig; 2023 Jul; 61(4):438-444. PubMed ID: 37119744
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
[TBL] [Abstract][Full Text] [Related]
31. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.
Benfield T; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Lindegaard B; Lundgren J; Meyer CN; Mohey R; Pedersen LM; Nielsen H; Nielsen SL; Obel N; Omland LH; Podlekareva D; Poulsen BK; Ravn P; Sandholdt H; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Christensen HR
Clin Infect Dis; 2021 Dec; 73(11):2031-2036. PubMed ID: 34111274
[TBL] [Abstract][Full Text] [Related]
32. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.
Frishman WH
Cardiol Rev; 2021 May-Jun 01; 29(3):109. PubMed ID: 33758124
[No Abstract] [Full Text] [Related]
33. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
[TBL] [Abstract][Full Text] [Related]
34. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
35. A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19.
Ngo DQ; Hamid K; Rana H; Cardinale M; Frenia D; Ghani N; Redel H
Can J Infect Dis Med Microbiol; 2022; 2022():9209618. PubMed ID: 35845297
[TBL] [Abstract][Full Text] [Related]
36. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
Troyer BS; Kovacic Scherrer N; Garavaglia J
J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
[No Abstract] [Full Text] [Related]
37. Use of Remdesivir in Myasthenia gravis and COVID-19.
Peters BJ; Rabinstein AA; DuBrock HM
Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
[TBL] [Abstract][Full Text] [Related]
39. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
40. Compassionate Use of Remdesivir in Children With Severe COVID-19.
Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
